

Poliomyelitis Therapeutic and Drug Pipeline Review H2

Poliomyelitis Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, December 23, 2016 /EINPresswire.com/ -- GET SAMPLE REPORT @

https://www.wiseguyreports.com/sample-request/839568-poliomyelitis-pipeline -review-h2-2016

Summary

Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis – Pipeline Review, H2 2016, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.



Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 3, 2, 5 and 7 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis

(Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Table of Contents
Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Poliomyelitis Overview 9

Therapeutics Development 10

Pipeline Products for Poliomyelitis - Overview 10

Pipeline Products for Poliomyelitis - Comparative Analysis 11

Poliomyelitis - Therapeutics under Development by Companies 12

Poliomyelitis - Therapeutics under Investigation by Universities/Institutes 14

Poliomyelitis - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Poliomyelitis - Products under Development by Companies 18

Poliomyelitis - Products under Investigation by Universities/Institutes 20

Poliomyelitis - Companies Involved in Therapeutics Development 21

...Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/839568-poliomyelitis-pipeline-review-h2-2016

Get in touch:

LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wisequyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.